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The mixed dopaminc (DA) agonist/antagonist tcrguridc acts as a I)A antagonist on normosensitivc receptors but shows DA 
agonistic properties at supersensitive DA receptors. Such a compound could offer an alternative to the treatment of Parkinson's 
disease with indirect or direct DA agonists. The present study compares the actions of terguride, 4-12 mg/kg i.p., in naive 
common marmoscts with its effects in animals rendered parkinsonian by administration of 1-methyl-4-phenyl-l,2,3,6-tetrahydro- 
pyridinc (MPTP), 2 months or 10 months previously, in order to test its antiparkinsonian efficacy. Tcrguride reduced locomotor 
activity in naive common marmosets, imilar to its effects in rodents and in line with the DA antagonistic activity of the 
compound. In marmosets treated with MPTP 2 months previously and exhibiting pronounced bchavioural motor deficits, 
terguride stimulated locomotor activity, showing DA agonistic properties under these conditions. In contrast, the locomotor 
activity of animals that had recovered from MPTP treatment 10 months previously was not altered by terguride. It is concluded 
that terguridc has anti-akinetic efficacy in this primate model of Parkinson's disease. In addition, terguride offers a unique 
opportunity to differentiate, pharmacologically, the extent of dopaminergic recovery from MPTP treatment in this primate 
species. 
MPTP (1-methyl-4-phcnyl-l,2,3,6-tetrahydropyridinc); Parkinsonism; Tcrguride; 
Dopamine D 2 receptors (mixed agonist/antagonist); (Common marmoset) 
I. Introduction 
The current treatment of Parkinson's disease with 
indirect or direct dopamine (DA) agonists (i.e., L-Dopa, 
lisuride, pergolide or bromocriptinc) is limited by side 
effects. Whereas somc initial adverse reactions uch as 
nausea and vomiting usually disappear due to rapid 
tolerance, the incidence of others such as fluctuations 
in motor performance and involuntary movements in- 
creases after long-term treatment with L-Dopa (Mars- 
den and Parkcs, 1976). Psychosis is another limiting 
side effect of all dopaminergic therapies, especially in 
elderly patients. A balanced stimulation of DA recep- 
tc.rs, taking into account the differential status of DA 
receptor sensitivity in the course of the disease, could 
lead to a more specific therapeutic effect and reduc- 
tion of side effects. 
Correspondence to: P.-A. lJJschmann, Schcring AG, Ncuropsy- 
chopharmacology, Postfach 65 03 11, D-1000 Berlin 65, F.R.G. Tel. 
49.30.468 2162, fax 49.30.4691 6738. 
Mixed DA agonists/antagonists, with terguridc be- 
ing the prototype compound, are promising for such an 
approach. Tcrguride, a derivative of the dopaminergic 
ergolinc lisuride, binds with high affinity to rat striatal 
DA 1) 2 and to a lesser extent to DA D~ binding sites 
(Valchfir ct al., 1987). The compound acts as a DA 
antagonist in normal rats but shows DA agonistic prop- 
erties in reserpine-treated rodents (Wachtcl and 
Dorow, 1983). In naive rats, terguride dose depen- 
dently inhibits locomotor activity. However, stimulation 
occurs after subchronic prctreatment with reserpine. 
Similarly, terguride does not induce stereotypies in rats 
treated acutely with reserpine, but does so after sub- 
chronic treatment with reserpine (Wachtel ct al., 1984). 
Furthermore, and in common with classical DA ago- 
nists, terguridc suppresses hyperprolactinaemia in fe- 
male rats pretreated with reserpine and induces con- 
tralateral rotations in rats injected unilaterally with 
6-hydroxydopaminc into the substantia nigra (Dlab~c 
and Krej(:i, 1980; lJSschmann et al., 1991a). 
Administration of 1-methyl-4-phenyl-l,2,3,6-tetrahy- 
dropyridine (MPTP) to man or non-human primates 
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(Davis et al., 1979; Langston et al., 1983; Burns et al., 
1983) including common marmosets (Jenner ct al., 
19841 induccs a parkinsonian syndromc duc to the 
selective destruction of nigrostriatal neurones, which 
causes a substantial decrease in the DA content of the 
caudate nucleus and putamen and a corresponding 
decrease in [~H]DA uptake (Jenner el al., 1984). The 
deficits in motor performance produced by MPTP 
trcatmcnt of common marmosets respond to classical 
anti-parkinsonian drugs such as L-Dopa in combina- 
tion with a peripheral decarboxylase inhibitor (Jenner 
et al., 1984), or DA rcccptor agonists such as (+) -  
PHNO (Nomoto et al., 19871, N-0437 (l.6schmann ct 
al., 1989) or the ergoline derivative lisuridc (L6sch- 
mann ct al., 1991b). The MPTP-treated monkey ap- 
pears to be the most suitable pharmacological model of 
Parkinson's disease currently available. 
Common marmosets recover from the initial symp- 
toms induced by MPTP treatment over a period of 
several months. This bchavioural recovery, is associated 
with increased DA turnover in the caudatc-putamcn 
(Jenner et al., 1984; Rose ct al., 19891 and is not 
reverscd by further treatment with MPTP (Ueki et al., 
19891. The present study was designed to test the 
hypothesis that the behavioural recovery in common 
marmosets after MPTP treatment would be associated 
with a change in their behavioural response to a mixcd 
DA agonist/antagonist. Wc therefore compared the 
actions of terguride in naive common marmosets to its 
effects in groups of animals exposed to MPTP either 2 
months or 10 months prior to the administration of 
terguride. The results obtained under these conditions 
are discussed in view of the pharmacological effects of 
tcrguride in patients. 
2. Materials and methods 
2.1. Animals 
Common marmosets (Callithrix jacchus) of either 
sex weighing 280-420 g and aged 6-10 years at the 
beginning of the study were used. The animals were 
housed in pairs or alone under standard conditions at a 
temperature of 27°C (+ I°C) and 50% relative humid- 
ity with a 12-h light-dark cycle (light on from 6:00 to 
18:00 h). The animals had free access to food pellets 
(Mazuri primate diet) and tap water, and in addition 
received a daily ration of fresh fruit and Mazuri mar- 
moset jelly. During MPTP treatment and throughout 
the following weeks the animals were hand-fed with 
Mazuri marmoset jelly and fresh fruit puree until they 
were able to maintain themselves. Electrolyte, nutrient 
and fluid balance were maintained by s.c. infusion of 
an electrolyte, amino acid and vitamin solution 
(Duphalyte, Duphar, UK) when necessary. 
2.2. Measurement of locomotor actit:ity 
Ix)comotor activity was measured simultaneously in
four aluminium cages (50 × 60 × 70 cm) with stainless 
steel grid doors (50 × 70 cm) identical to thc animals' 
home cages but equipped with eight horizontally orien- 
tated sets of infrared photocells. Across the cage three 
beams wcrc located at floor level and one along each 
of the two pcrchcs. Other beams were directed from 
front-to-back of the cage at floor level and abc~ve ach 
pcrch. The number of light beam interruptions due to 
the animal's movements were accumulated in 10-min 
intervals and recorded for 360 rain, using a Com- 
modore CBM 4032 computer. The animals were al- 
lowed to acclimatize to the test cage for a minimum of 
30 rain prior to drug treatment. 
2.3. Behat:ioural obsercations 
In parallcl to the automated recording of locomotor 
activity the animals were observed under blinded con- 
ditions through a one-way mirror. Motor behaviour was 
rated qualitatively to determine the presence or ab- 
sence of stereotypy, head twitches, wet-dog shakes or 
grooming, oral movements, co-ordination of movement 
(good/impaired) and other obvious motor signs in 5- 
min intervals for 360 rain after drug administration. 
The maximal score for each item was 72. 
2.4. Drugs and solutions 
The following compounds were used: MPTP (l- 
methyl-4-phenyl- 1,2,3,6-tetrahydropyridine hydrochlo- 
ride; Schering AG) and tcrguride (Sobering AG). MPTP 
was dissolved in sterile physiological saline and tcr- 
guridc was suspended in sterile physiological saline 
containing 10(I g/1 polycthoxylated castor oil (Cremo- 
phor EL, BASF, FRG). All solutions were prepared 
immediately before administration. 
2.5. MPTP treatment 
The animals were treated with MPTP in doses of 2 
mg/kg  s.c. daily for up to 6 days. Since the response of 
individual animals differed markedly, variable dose 
regimes were applied to obtain comparable initial mo- 
tor deficits. Impairment of motor function was quanti- 
fied daily with a rating scale (L/ischmann ctal . ,  1989). 
The animals were treated until they reached a maximal 
disability score of 18 24 h after the last MPTP injec- 
tion. The cumulative doses administered ranged from 8 
to 12 mg/kg.  After MPTP treatment he animals re- 
covered from acute effects over a period of some 
weeks. During the following months a further gradual 
recovery, from the MPTP effects was obscrvcd. One 
group of three animals was tested 2 months (group A) 
aad a second group of thrcc animals 10 months (group 
B) after exposure to MPTP. 
2.6. Drug treatments 
A group of four marmosets was treated with vehicle 
aad one of the three doses of tcrguridc (4.0, 8.0 or 12.0 
mg/kg  i.p.) ovcr the following weeks, allowing 1 week 
recovery between experiments. Treatments wcrc ran- 
d~mizcd within the group. MPTP-trcatcd marmosets 
were tested either 2 months (group A, N = 3) or 10 
months (group B, N = 3) after MPTP treatment with 
vehicle or one of the three doses of tcrguride (4.0, 8.0 
or 12.0 mg/kg  i.p.) in a identical design. All experi- 
ments started at 11:00 a.m. and finished at 5:00 p.m. 
2. Z Data analysis 
The means _+ S.E.M. wcrc calculated for time 
courses and accumulated locomotor counts of the dif- 
ferent treatment groups. Statistical differences were 
calculated for accumulated locomotor counts by the 
non-parametric Page test for non-independent data. 
lntraindividual monotone trends of treatment effects 
were detected using the ordered alternative: vehicle < 
4.0 < 8.0 < 12 mg/kg,  using exact distributions fol- 
lowed by sequential tests against two alternative hy- 
potheses (vehicle < 4.0 < 8.0 mg/kg) or (vehicle < 4.0 
and 8.0 < 12.(I mg/kg)  when appropriate. 
3. Results 
When adapted to the environment of the test cages, 
naive common marmosets showed very little locomotor 
activity when not disturbed. Injection of vehicle was 
followed by a 30-min period of exploratory activity but, 
~ 300 ,~  
z 260 ]0  ~ 
2 ~4o-  1 , lr 
~ "[ 00 
E 60 
~ 20 
~ -20 
~0 
TTLI ~I 
60 120 180 240 300 360 
Time (rain) 
Fig. 1. Mean locomotor activity counts (+S.E.M. .  N = 4) accumu- 
]aled in 10-rain intervals for 180 rain of naive common marmosets 
treated with vehicle (.~) or 4.0 (e), 8.0 (/~) and 12.0 (• )  mg/kg  of 
tc:guride, respectively. Error bars for the treatment groups are 
omilted for clarity but were within the same range as those shown for 
the vehicle group. 
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TABLE 1 
Median stereotypy scores with the range in parentheses over 360 rain 
after treatment of common marmosets with terguridc. 
Treatment Normal 2 months 10 months 
post MPTP post MPTP 
Vehicle 0 (0) 0 (0) 0 (0) 
4 mg/kg  0 (0) 4 (5) 3 (3) 
8 mg/kg  0 (0) 7 (5) 2 (3) 
12 mg/kB 0 (0) 21 (14) 4 (1) 
thereafter, little or no activity for up to 180 min. This 
exploratory activity was dose dependently reduced by 
terguride 4.0, 8.0 and 12.0 mg/kg  i.p. (figs. 1 and 4). At 
later times vehicle-treated animals were more active 
whereas terguride-treated animals showed almost com- 
plete akinesia. 
Prior to behavioural testing, all animals of group A 
(treatment with MPTP 2 months before the experi- 
ment) showed a reduction in basal locomotor activity 
and exhibited slower and less coordinated movements, 
reduced checking movements of the head and eye- 
blinks as well as abnormal postures of some parts of 
the body. The behavioural deficits were different in 
group B (treatment with MPTP 10 months before 
testing). Locomotor activity was still reduced in one of 
these animals whereas another showed signs of hyper- 
excitability and unrest. The behaviour of the third 
animal was not different from that of controls. 
Animals treated with MPTP 2 months prior to the 
experiment (group A) showed reduced locomotor activ- 
ity when exposed to vehicle. Terguridc stimulated loco- 
motor activity in the first I80 min after administration. 
Because stereotyped movements were elicited by the 
higher doses tested, 4.0 mg/kg  of tcrguride was most 
effective (fig. 4 and table 1). The stimulatory effect of 
tcrguride was more pronounced uring the last 3 h of 
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Fig. 2. Mean locomotor activity counts (_,'. S.E.M., N = 3) accumu- 
laled in 10-min inlcrvals for 360 rain of common marmosets pre- 
treated with MPTP 2 months prior to the adminislration of vehicle 
(o )  or 4.0 (e), 8.0 ( ,~ ) and 12.0 ( • ) mg/kg  of terguride, respectively. 
Error bars for the higher doses are omitted for clarity but were 
within the same range as those shown for 8.0 mg/kg  or vehicle i.p. 
(note the difference in scale to fig. 1). 
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Fig. 3. Mean locomotor activity counts (+ S.E.M., N 3) accumu- 
lated in 10-min intc~,als for 360 min of common marmosets pro- 
treated with MPTP 10 months prior to the administration f vehicle 
(o) or 4.0 (~), 8.0 ( ~ ) and 12.0 (~ ) mg/kg of terguridc, respccti~ ely. 
Error bars for the higher doses are omitted lbr clarity but wcrc 
within the same range as those shown for 8.13 mg/kg or vehicle i.p. 
the observation period (fig. 2). Vehicle-treated animals 
showed some activity at this time of day, when they are 
usually fed. Marmosets treated with 4.0 and 8.0 mg/kg  
of terguride were clearly stimulated. The presence of 
stcrcotypics (table 11 resulted in a smaller stimulation 
of  locomotion after administration of 12 mg/kg  of 
tcrguridc i.p. (fig. 5). 
The basal locomotor activity of common marmosets 
treated with MPTP 10 months prior to the experiment 
(group B) was variable, leading to somewhat higher 
activity counts after vehicle treatment as compared 
with controls and animals of group A (figs. 3 and 4). 
Treatment with terguride reduced locomotor activity at 
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Fig. 4. Mcau locomotor activity counts (= S.E.M.) accumulated over 
180 in for the data shown in figs. 1-3. All groups of common 
marmosets wcrc treated with vehicle (open columns), 4.0 (dense 
hatched columns), 8.11 (hatched columns) and 12.0 (crossed columns) 
mg/kg of terguride. In naive animals tcrguridc dose dependently 
reduced locomotor activity (P < 13.01, Page test, ordered alternative: 
vehicle > 4.0 > 8.13 > 12i1 mg/kg of tcrguride). In common mar- 
moscts treated with MIrTP 2 months prior to the experiment, tel'- 
guride stimulated locomotor activity at the lowest dose tested (4.0 
mg/kg i.p., P < 0.05, Page test; ordered alternative: vehicle < 4.0 and 
8.0 < 12.0 mg/kg of terguridc). In animals exposed to MPTP 113 
months prior to the experiment, terguride rednccd locomotor actMty 
up the highest dose tested allhough the effect was not significant. 
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Fig. 5. Mean locomotor activity counts (~S.E.M. ,  N = 31 accnmu- 
lated over 360 min for the data shown in figs. 2 aud 3. Both groups of 
common marmosets wcrc treated with vehicle (open columns), 4.0 
(dense hatched columns). 8.0 (hatched colunms) and 12.0 (crossed 
colunms) mg/kg of tcrguride. In animals treated with MPTP 2 
months prior to the experiment, tcrguridc learly stimulated locomo- 
tor activity at ~he lower doses tested (4.0 and 8.0 mg/kg i.p.). 
Ilowcvcr, due to the variability of iudividual animal responses, this 
effect was not statistically significant. In common marmosets exposed 
to MPTP 10 months prior to the experiment, terguridc had no effect 
upon locomotor activity. 
all doses tested, although the effect did not seem to be 
dose-dependent.  During the second 3-h period, ter- 
guride showed a tendency to stimulate locomotor activ- 
ity. Again, this effect was not significant (figs. 3 and 5) 
for the 6-h observation period. None of the doses of 
terguride tested induced pronounced stereotyped 
movements in this group of animals (table 1). 
4. D iscuss ion  
In rodents without lesions, terguride has DA antag- 
onistic properties, resulting in a reduction of locomotor 
activity and in catalepsy when higher doses are admin- 
istered. In line with these findings, the compound 
reduces exploratory locomotor activity of normal com- 
mon marmosets. This depressant effect Iasts up to 6 h. 
DA agonistic properties arc unmasked in rodents pre- 
treated subchronically with reserpine (Wachtel et al., 
1984). It is likely that the depletion of monoaminergic 
terminals may lead to an increased sensitivity of postsy- 
naptic receptors. The anti-parkinsonian ctivity of ter- 
guride in the MPTP-treated primate, the most reliablc 
model fl)r Parkinson's disease at present available, has 
been shown previously. The compound induces rota- 
tions in monkeys rendered hcmiparkinsonian by intrac- 
arotid infusion of MPTP (Brihckc et al., 1988). In 
accord with these findings, our data indicate that DA 
agonistic effects in the MPTP-trcatcd common mar- 
moset arc also critically dependent  on the receptor 
status. A clear stimulatory effect was only seen in 
animals treated 2 months previously with MPTP when 
they had not recovered bchaviourally from the Ml r fP  
treatment. In the first 3 h, 4 mg/kg  of terguride 
produced the greatest response (fig. 4) whereas in the 
6-h period 4 and 8 mg/kg stimulated locomotor activ- 
il.y (fig. 5). In animals that had recovered from MPTP 
treatment given 10 months previously, tcrguride inhib- 
i,.cd locomotor activity in the first 3 h, as it did in 
formal marmosets, although this effect was not statisti- 
cally significant, llowever, in the 6-h period, all doses 
tested slightly stimulated locomotor activity, a response 
consistent with the weak DA agonistic effects of tcr- 
guride under these conditions. We hypothesize that the 
bchavioural recovery of common marmosets i accom- 
panied by a normalization of receptor sensitivity duc to 
changes in either the binding affinity or the coupling of 
receptors to second messenger systems. Thus, in ani- 
raals recovered from prior MPTP treatment, the in- 
creased I)A turnover (Rose et al., 1989) could lead to a 
higher availability of DA and subsequent normalization 
of the sensitivity of presynaptic autoreceptors. Under 
these conditions tcrguride would act as autoreceptor 
agonist, resulting in a reduced I)A release and inhibi- 
tion of locomotor activity during the initial 3-h period. 
In the second 3-h period, tcrguridc would exert weak 
DA agonistic properties at postsynaptic receptors. 
An alternative xplanation involves the partial DA 
agonistic properties of terguride. Thus, the increased 
DA turnover could lead to a higher availability of DA, 
with terguride antagonizing the effects of endogenous 
I)A. The initial inhibition of locomotor activity could 
be explained by such a phenomenon. Since terguridc 
did not reduce but slightly increased locomotor activity 
in recovered common marmosets over the 6-h period, 
the latter hypothesis eems less likely. 
Two faccts of the effects of tcrguridc arc of interest 
when compared with the effects of direct DA agonists 
such as (+) -PHNO (Nomoto et al., 1987) in this animal 
raodcl. First, tcrguridc did not cause a rapid and 
sustained locomotor hyperactivity even with the rela- 
tively high doses used. Second, the normal diurnal 
pattern of locomotor activity was preserved. Increased 
activity after treatment with terguride was seen during 
periods of higher basal locomotor activity nnder con- 
trol conditions. Both observations contrast with the 
stimulatory effect on locomotor activity seen in reser- 
pinizcd-rodents and are compatible with the idea that 
terguride 'enables' voluntary locomotion in the 
MPTP-treated marmoset rather than causes hyperstim- 
ulation. This atypical pharmacological profile, in which 
DA agonistic and DA antagonistic properties arc com- 
bined in one molecule, has been described as mixed 
DA agonism/antagonism in rodents. Our data show 
similar effects of terguride in a primate species. 
The unique pharmacological profile of terguridc 
suggests an interesting range of possible indications, 
some of which have already been tested in clinical 
trials. Like classical DA agonists, single doses of tcr- 
guride ranging from 0.25 to 1.0 mg lower prolactin 
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levels in humans and produce endocrine ffects identi- 
cal to those seen with bromocriptinc, but with less side 
effects. In a double-blind cross-over study, subjects 
could not distinguish the lower tcrguridc doses from 
placebo and 1 mg of tcrguridc was always preferred to 
2.5 mg bromocriptinc (Ciccarclli et al., 1988). Clinical 
observations confirm that terguride is useful in the 
treatment of hyperprolactinaemic conditions including 
prolactinomas (Dallabonzana et al., 1986). Antiparkin- 
sonian effects have been reported when terguride was 
used as monotherapy or combined with L-Dopa in 
advanced isease (Corsini et al., 1985). In open clinical 
trials in paticnts with Parkinson's disease, especially in 
elderly patients (Briicke et al., 1986), there was a low 
frequency of typical dopamincrgic side effects such as 
nausea, cmcsis or orthostatic hypotension. However, in 
a double-blind study in dc now) patients terguride was 
better tolerated but less active than lisuride after 3 
months of therapy and its possible long-term effects 
are still trader investigation (U.K. Rinnc, personal 
communication). In placebo-controlled double-blind 
studies in patients with motor fluctuations, terguridc 
added to L-Dopa had a significant effect on disability 
and also improved wearing off and dyskinesias (E. 
Martignoni and G. Nappi, personal communication). 
In these studies antidyskinetic and anti-akinctic effects 
of terguridc wcrc obse~'ed in the same patients. Tcr- 
guridc had very pronounced anti-dyskinetic effects 
without interference with the anti-akinctic effects of 
L-Dopa in parkinsonian patients with motor fluctua- 
tions as shown in a double-blind placebo-controlled 
study (Baronti et al., 1989 and submitted for publica- 
tion). Tcrguridc has positive effects on tardive dyskinc- 
sia even in the presence of ncurolcptic drugs (Silk6 ct 
al., 1987). Finally, in an open clinical trial, including 11 
patients with chronic schizophrenia nd marked nega- 
tive symptoms, tcrguride improved symptomatology in 
eight patients on the scale for assessment of negative 
symptoms (SANS). In none of the patients were psy- 
chotic symptoms elicited and the compound was well 
tolerated (Olbrich and Schanz, 1988). 
Mixed DA agonist/antagonists may have good anti- 
parkinsonian actions with fewer side effects, especially 
in patients susceptible to motor fluctuations, dyskine- 
sias, psychosis or enhanced sensitivity towards 
dopamincrgic drugs. 
In conclusion, the MPTP-treated common mar- 
moset offers a useful pharmacological model and is of 
predictive value for the characterization of not only 
classical direct DA agonists but also mixed DA ago- 
nist/antagonists. Tcrguride can be used in a pharma- 
cological in vivo test for the assessment of the sensitiv- 
ity status of central DA receptors in MPTP-trcated 
primates. Tcrguride could also be valuable for the 
assessment of the function of dopaminergic cell trans- 
plants. 
252 
Acka~owledgements 
K.W. Lange was supported by the European Science Foundation 
and the European Medical Research Council. P.A. ISSschmann was a 
visiting research fellow at the University I)epartment of Clinical 
Neurology, Institute of Neurology, The National Hospital, Queen 
Square, London. 
References 
Baronti, F., M.M. Mouradim. S. Brughitta, K.E. Conant, M. Giaffra 
and T.N. Chase, 1989. Partial dopaminc agonist therapy of lcv- 
odopa-induced dyskincsia, Neurology 39, 556. 
Bri.icke, T., W. Daniclczyk, M. Simfinyi, E. Sofic and P. Ricdcrcr, 
i986, Terguride: partial dopaminc agonist in the treatment of 
Parkinson's disease, in: Advances in Neurology, Vol. 45, eds. 
M.D. Yahr and K.J. Bcrgmann (Raven Press. New York) p. 573. 
Brl.icke, T., K. Bankicwicz, J. Har,,ey-White and 1. Kopin, 1988, The 
partial dopamine agonist tcrguride in the MPTP-induccd hcmi- 
parkinsonian monkey model, Eur. J. Pharmacol. 148, 445. 
Burns, R.S., C.C. Chiuch, S.P. Markey, M.H. Ebcrt, D.M. Ja- 
cobowitz and I.J. Kopin, 1983, A primate model of parkinsonism: 
selective destruction of dopaminergic neurons in the pars com- 
pacta of the substantia nigra by N-methyl-4-phcnyl-l,2,3,6-tetra- 
hydropyridinc, Proc. Natl. Acad. Sci. U.S.A. 8(I, 4546. 
Ciccarclli, E., R. Touzcl, M. Bcsser and A. (~,rossman. 1988, Ter- 
guride - a new dopamine agonist drug: a comparison of its 
ncuroendocrinc and side effect profile with bromocriptinc, Fcrtil. 
Steril. 49. 589. 
Corsini, G.U.. U. Bonuccclli, E. Rainer and M. Del Zompo. 1985, 
Therapeutic efficacy of a partial dopaminc agonisl in dang-free 
parkinsonian patients..1. Net, ral Transm. 64, 11)5. 
I)allahonzana. D., A. Liuzzi, G. Oppizzi. R. Cozzi, G. Verde. P. 
Chiodini, E. Rainer. R. Dorow and R. llorowski, 1986. Chronic 
treatment of pathological hypcrprolactincmia and acromegaly 
with the new ergot derivative tcrguride. J. Clin. Endocrinol. 
Mctab. 63, 1002. 
Davis, G.C., A.C. Williams, S.P. Markey, M.ll. Ebcrt, t';.D. Cainc, 
C.M. Rcichert and l.J. Kopin, 1979, Chronic parkinsonism sec- 
ondary to intravenous injections of meperidinc analogues, Psy- 
chiat. Res. 1. 249. 
Dlaba(:. A. and I. Krej(:i, 1980, Central dopaminergic effects of 
ergolinc derivatives, Activ. Nerv. Sup. (P,aha) 22, 208. 
.lcnner, P., N.M.J. Rupniak, S. Rose, E. Kelley, G. Kilpatrick, A. 
Lccs and C.D. Marsden 1984, 1-Methyl-4-phcnyl-l,2,3,6-tetrahy- 
dr~pyridine-induccd parkinsonism in the common marmoset, 
Ncurosci. Lett. 50, 85. 
I,angston, J.W., P. Ballard, J.W. Tctrud and I. Iv, via. 1983, Chronic 
parkinsonism in humans due to a product of mepcridinc-analog 
synthesis, Science 225, 1481). 
L6schmann, P.-A., P.N. Chong, M. Nomoto, P.G. Tepper, A.S. 
flora, P. Jenner and C.D. Marsden, 1989, Stercoselective r versal 
of MPTP-induccd parkinsonism in the marmoset after dermal 
application of N-0437. Eur. J. Pharmacol. 166, 373. 
L/'Jschamnn, P.-A., K.J. Rcttig, R. Horowski, H. Wachtcl, K.W. 
I.ange, P. Jenner and C.D. Marsden, 1991a, Terguridc, a 
dopaminc partial agonist for the treatment of Parkinson's dis- 
ease, in: Basic, Clinical, and Therapeutic Aspects of Alzheimer's 
and Parkinson's Diseases, Vol. 2, eds. T. Nagatsu, A. Fisher anti 
M. Y<~shida (Plenum Pt, blishing Corporation, New Y¢~rk) p. 569. 
I.fischmann, P.-A., K.J. Retlig, II. Wachtel, R. Dt~row, P. Jenner and 
C.D. Marsden, 1991b, 1.isuride and protcrguride reverse MPTP- 
induced parkinsonism in the common marmoset, in: Basic, Clini- 
cal. and Therapeutic Aspects of Alzhcimcr's and Parkir:son's 
Diseases, Vol. 2, eds. T. Nagatsu, A. Fishe, and M. Yoshida 
(Plenum Publishing Corporatk~n, New York) p. 565. 
Marsdcn, C.D. and J.D. Parkes, 1976, 'On-ofF effects i~ palients 
with Parkinson's disease on chronic lcvodopa therapy, Lancet 1, 
292. 
Nomot~. M., S. Stahl, P. Jenner and C.D. Marsdcn, I987, Anti- 
parkinsonian activity of (+)-PItNO in the MPTP treated com- 
mon marmoset, Movement Di.,~rders 2, 37. 
Olbrich, R. and II. Schanz, 1988, The effect of the partial dopaminc 
agonist tergt, ridc on negative symptoms in schizophrenics, Phar- 
macopsychiat~y 21. 389. 
Rose, S., M. Nomoto, E. Kelly, G. Kilpatrick, ?. Jenner and C'.D. 
Marsden, 1989. Increased caudate dopaminc turnover may c~m- 
tribute to lhC recover' of motor function in marmosets treated 
with the dopamincrgic neurotoxin MPTP, Neurosci. I.ett. 101, 
305. 
S~ik~], E., R. Jokinen, V. R~ikk61~iinen, U.K. Rinnc and I. Suchy, 
1987, The effect of terguride in tardive dyskinesia. Acta Ncurol. 
Scand. 77 (Suppl.). 93. 
Ueki, A.. P.N. Chong, A. AIbanese, S. Rose. J.K. Chivcrs, P. Jenner 
and C.D. Marsdcn. 1989, Further treatment with MPTP does not 
produce parkinsonism in marmosets showing behavioural recov- 
ery from motor deficits induced by an earlier exposure to the 
toxin. Ncuropharmacology 28, 1089. 
Valchfir, M., M. Vrseckfi, 1. Krej6~ and A. Dlaba& 1987, Binding 
characteristics of the dopamine agonist/antagonist [3H]tcrguride 
(transdihydrolisuridc) in the rat slriatu,n, Eur. J. Pharmacol. 136, 
97. 
Wachtel, It. and R. Dorow, 1983, Dual action on central dopamine 
function of transdihydrolisuride, a 9,10-dihydrogenatcd analogue 
of the ergot dopaminc agonist lisuridc, Life Sci. 32, 42l. 
Wachtel, lI., K.-J. Rettig and A. Seltz, 1984, The central dopamine 
agonistic action of transdihydrolisuridc is unmasked at supersen- 
sitive receptors, Naunyn-Schmiedeh. Arch. l'harmacol. 325 
(Suppl.) 80. 
